How to conduct research on overdiagnosis. A keynote paper from the EGPRN May 2016, Tel Aviv: ‘Life can only be understood backwards; but it must be lived forwards’ Søren Kierkegaard (Danish philosopher 1813–1855)

European Journal of General Practice

Volumn 23, Issue 1, 2017, Pages 78-82

  Brodersen, John ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Primary Health Care Research Unit   (Denmark)

Author keywords

Overdiagnosis; overtreatment; overuse; qualitative research; quantitative research

Indexed keywords

ARTICLE; DIAGNOSTIC ERROR; HUMAN; MEDICAL ERROR; OVERDIAGNOSIS; OVERTREATMENT; PROGNOSIS; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RESEARCH; HEALTH SERVICE; MASS SCREENING; METHODOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UNNECESSARY PROCEDURE;

HUMANS; MASS SCREENING; MEDICAL OVERUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; UNNECESSARY PROCEDURES;

EID: 85015954038     PISSN: 13814788     EISSN: 17511402     Source Type: Journal    
DOI: 10.1080/13814788.2017.1290795     Document Type: Article

References (27)

1. Welch HG, Schwartz L, Woloshin S, Overdiagnosed. Making people sick in the pursuit of health. Boston:Beacon Press; 2011.
2. Doust J, Glasziou P., Is the problem that everything is a diagnosis? Aust Fam Physician. 2013;42:856–859.
3. Brodersen J, Schwartz LM, Woloshin S., Overdiagnosis:How cancer screening can turn indolent pathology into illness. APMIS. 2014;122:683–689.
4. Carter SM, Rogers W, Heath I, et al. The challenge of overdiagnosis begins with its definition. Br Med J. 2015;350:h869.
5. Reventlow SD, Hvas L, Malterud K., Making the invisible body visible. Bone scans, osteoporosis and women's bodily experiences. Soc Sci Med. 2006;62:2720–2731.
6. Hansson A, Brodersen J, Reventlow S, et al. Opening Pandora’s box:The experiences of having an asymptomatic aortic aneurysm under surveillance. Health Risk Soc. 2012;14:341–359.
7. Brodersen J, Thorsen H, Kreiner S., Consequences of screening in lung cancer:Development and dimensionality of a questionnaire. Value Health. 2010;18:601–612.
8. Brodersen J, Thorsen H., Consequences of screening in breast cancer (COS-BC):Development of a questionnaire. Scand J Prim Health Care. 2008;26:251–256.
9. Brodersen J, Siersma VD., Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med. 2013;11:106–115.
10. Carter JL, Coletti RJ, Harris RP., Quantifying and monitoring overdiagnosis in cancer screening:A systematic review of methods. BMJ. 2015;350:g7773.
11. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328.
12. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–990.
13. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality:Results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2017–2035.
14. Zahl PH, Jorgensen KJ, Maehlen J, et al. Biases in estimates of overdetection due to mammography screening. Lancet Oncol. 2008;9:199–201.
15. Shoag JE, Mittal S, Hu JC., Reevaluating PSA testing rates in the PLCO Trial. N Engl J Med. 2016;374:1795–1796.
16. Ilic D, Neuberger MM, Djulbegovic M, et al. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;(1):CD004720.
17. Gotzsche PC, Jorgensen KJ., Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;(6):CD001877.
18. Heleno B, Thomsen MF, Rodrigues DS, et al. Quantification of harms in cancer screening trials:Literature review. BMJ. 2013;347:f5334
19. Esserman L, Shieh Y, Thompson I., Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302:1685–1692.
20. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish lung cancer screening trial:Status after five annual screening rounds with low-dose CT. Thorax. 2012;67:296–301.
21. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193:542–551.
22. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer epidemic-screening and overdiagnosis. N Engl J Med. 2014;371:1765–1767.
23. Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality:A randomized clinical trial. JAMA. 2014;312:606–615.
24. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33:111–121.
25. McCaffery KJ, Jansen J, Scherer LD, et al. Walking the tightrope:Communicating overdiagnosis in modern healthcare. Br Med J. 2016;352:i348.
26. Harris RP, Sheridan SL, Lewis CL, et al. The harms of screening:A proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014;174:281–285.
27. Jessen LKH, Harris R, Brodersen J. Consequences of overdiagnosis. Paper presented at:Preventing overdiagnosis 3rd international conference; 2015; Washington (DC).